Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas

被引:46
|
作者
Colomba, A. [1 ,2 ]
Courilleau, D. [1 ,2 ]
Ramel, D. [1 ,2 ]
Billadeau, D. D. [3 ,4 ]
Espinos, E. [1 ,2 ]
Delsol, G. [1 ,2 ]
Payrastre, B. [1 ,2 ]
Gaits-Iacovoni, F. [1 ,2 ]
机构
[1] CHU Purpan, Ctr Physiopathol Toulouse Purpan, INSERM,U563, Dpt Oncogenese Signalisat & Innovat Theraperut, F-31024 Toulouse 3, France
[2] Univ Toulouse III Paul Sabatier, IFR30, Toulouse, France
[3] Mayo Clin, Coll Med, Div Dev Oncol Res, Rochester, MN USA
[4] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN USA
关键词
anaplastic large cell lymphomas; NPM-ALK; Rho GTPases; Vav3;
D O I
10.1038/sj.onc.1210921
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The majority of anaplastic large cell lymphomas (ALCLs) express the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion protein, which is oncogenic due to its constitutive tyrosine kinase activity. Transformation by NPM-ALK not only increases proliferation, but also modifies cell shape and motility in both lymphoid and fibroblastic cells. We report that the Rac1 GTPase, a known cytoskeletal regulator, is activated by NPM-ALK in ALCL cell lines (Karpas 299 and Cost) and transfected cells (lymphoid Ba/F3 cells, NIH-3T3 fibroblasts). We have identified Vav3 as one of the exchange factors involved in Rac1 activation. Stimulation of Vav3 and Rac1 by NPM-ALK is under the control of Src kinases. It involves formation of a signaling complex between NPM-ALK, pp60(c-src), Lyn and Vav3, in which Vav3 associates with tyrosine 343 of NPM-ALK via its SH2 domain. Moreover, Vav3 is phosphorylated in NPM-ALK positive biopsies from patients suffering from ALCL, demonstrating the pathological relevance of this observation. The use of Vav3-specific shRNA and a dominant negative Rac1 mutant demonstrates the central role of GTPases in NPM-ALK elicited motility and invasion.
引用
收藏
页码:2728 / 2736
页数:9
相关论文
共 10 条
  • [1] Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas
    A Colomba
    D Courilleau
    D Ramel
    D D Billadeau
    E Espinos
    G Delsol
    B Payrastre
    F Gaits-Iacovoni
    Oncogene, 2008, 27 : 2728 - 2736
  • [2] NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
    Haque, Moinul
    Li, Jing
    Huang, Yung-Hsing
    Almowaled, Meaad
    Barger, Carter J.
    Karpf, Adam R.
    Wang, Peng
    Chen, Will
    Turner, Suzanne D.
    Lai, Raymond
    CANCERS, 2019, 11 (08)
  • [3] NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma
    Pearson, Joel D.
    Lee, Jason K. H.
    Bacani, Julinor T. C.
    Lai, Raymond
    Ingham, Robert J.
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2011, 4 (02): : 124 - 133
  • [4] Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma
    Bohling, Sandra D.
    Jenson, Stephen D.
    Crockett, David K.
    Schumacher, Jonathan A.
    Elenitoba-Johnson, Kojo S. J.
    Lim, Megan S.
    LEUKEMIA RESEARCH, 2008, 32 (03) : 383 - 393
  • [5] Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth
    Riera, Ludovica
    Lasorsa, Elena
    Ambrogio, Chiara
    Surrenti, Nadia
    Voena, Claudia
    Chiarle, Roberto
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (34) : 26441 - 26450
  • [6] CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas
    Kuravi, Sudhakiranmayi
    Parrott, Elizabeth
    Mudduluru, Giridhar
    Cheng, Janice
    Ganguly, Siddhartha
    Saunthararajah, Yogen
    Jensen, Roy A.
    Blagg, Brian S.
    McGuirk, Joseph P.
    Balusu, Ramesh
    BLOOD CANCER JOURNAL, 2019, 9 (2)
  • [7] BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL
    Garland, Gavin D.
    Ducray, Stephen P.
    Jahangiri, Leila
    Pucci, Perla
    Amos Burke, G. A.
    Monahan, Jack
    Lai, Raymond
    Merkel, Olaf
    Schiefer, Ana-Iris
    Kenner, Lukas
    Bannister, Andrew J.
    Turner, Suzanne D.
    CANCERS, 2022, 14 (01)
  • [8] Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α
    Lopez-Haber, Cynthia
    Barrio-Real, Laura
    Casado-Medrano, Victoria
    Kazanietz, Marcelo G.
    MOLECULAR AND CELLULAR BIOLOGY, 2016, 36 (15) : 2011 - 2026
  • [9] Phosphatidylinositol 3,4,5-Triphosphate-Dependent Rac Exchanger 1 (P-Rex-1), a Guanine Nucleotide Exchange Factor for Rac, Mediates Angiogenic Responses to Stromal Cell-Derived Factor-1/Chemokine Stromal Cell Derived Factor-1 (SDF-1/CXCL-12) Linked to Rac Activation, Endothelial Cell Migration, and in Vitro Angiogenesis
    Carretero-Ortega, Jorge
    Walsh, Colin T.
    Hernandez-Garcia, Ricardo
    Reyes-Cruz, Guadalupe
    Brown, Joan Heller
    Vazquez-Prado, Jose
    MOLECULAR PHARMACOLOGY, 2010, 77 (03) : 435 - 442
  • [10] PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) Activity Promotes Breast Cancer Cell Proliferation and Tumor Growth via Activation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Signaling
    Liu, Heng-Jia
    Ooms, Lisa M.
    Srijakotre, Nuthasuda
    Man, Joey
    Vieusseux, Jessica
    Waters, JoAnne E.
    Feng, Yue
    Bailey, Charles G.
    Rasko, John E. J.
    Price, John T.
    Mitchell, Christina A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (33) : 17258 - 17270